LUCY SCIENTIFIC DISCOVERY IN (LSDI) Fundamental Analysis & Valuation

NASDAQ:LSDI • CA54960E2033

Current stock price

0.5139 USD
-0.16 (-23.29%)
At close:
0.4552 USD
-0.06 (-11.42%)
After Hours:

This LSDI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. LSDI Profitability Analysis

1.1 Basic Checks

  • LSDI had negative earnings in the past year.
  • In the past year LSDI has reported a negative cash flow from operations.
LSDI Yearly Net Income VS EBIT VS OCF VS FCFLSDI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M -8M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -263.59%, LSDI is doing worse than 93.26% of the companies in the same industry.
  • With a Return On Equity value of -13916.75%, LSDI is not doing good in the industry: 87.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -263.59%
ROE -13916.75%
ROIC N/A
ROA(3y)-104.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LSDI Yearly ROA, ROE, ROICLSDI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -500 -1K -1.5K -2K -2.5K

1.3 Margins

  • With a Gross Margin value of 14.97%, LSDI perfoms like the industry average, outperforming 49.22% of the companies in the same industry.
  • LSDI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LSDI Yearly Profit, Operating, Gross MarginsLSDI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -20K -40K -60K -80K -100K

4

2. LSDI Health Analysis

2.1 Basic Checks

  • LSDI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • LSDI has more shares outstanding than it did 1 year ago.
  • LSDI has a better debt/assets ratio than last year.
LSDI Yearly Shares OutstandingLSDI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 500K 1M 1.5M
LSDI Yearly Total Debt VS Total AssetsLSDI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M 8M

2.2 Solvency

  • LSDI has an Altman-Z score of -21.67. This is a bad value and indicates that LSDI is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of LSDI (-21.67) is worse than 86.01% of its industry peers.
  • LSDI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -21.67
ROIC/WACCN/A
WACC7.34%
LSDI Yearly LT Debt VS Equity VS FCFLSDI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 2M -2M 4M -4M -6M

2.3 Liquidity

  • LSDI has a Current Ratio of 0.38. This is a bad value and indicates that LSDI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of LSDI (0.38) is worse than 95.85% of its industry peers.
  • LSDI has a Quick Ratio of 0.38. This is a bad value and indicates that LSDI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.38, LSDI is doing worse than 94.82% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.38
LSDI Yearly Current Assets VS Current LiabilitesLSDI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M 5M

1

3. LSDI Growth Analysis

3.1 Past

  • The earnings per share for LSDI have decreased strongly by -96.67% in the last year.
EPS 1Y (TTM)-96.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 23.49% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y78.1%
EPS Next 2Y34.54%
EPS Next 3Y23.49%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LSDI Yearly Revenue VS EstimatesLSDI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 10M 20M 30M 40M
LSDI Yearly EPS VS EstimatesLSDI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 -2 -4 -6

1

4. LSDI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for LSDI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LSDI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LSDI Price Earnings VS Forward Price EarningsLSDI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LSDI Per share dataLSDI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as LSDI's earnings are expected to grow with 23.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.54%
EPS Next 3Y23.49%

0

5. LSDI Dividend Analysis

5.1 Amount

  • LSDI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

LSDI Fundamentals: All Metrics, Ratios and Statistics

LUCY SCIENTIFIC DISCOVERY IN

NASDAQ:LSDI (6/28/2024, 8:12:35 PM)

After market: 0.4552 -0.06 (-11.42%)

0.5139

-0.16 (-23.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-13
Earnings (Next)N/A
Inst Owners7.28%
Inst Owner Change0%
Ins Owners65.53%
Ins Owner Change0%
Market Cap904.46K
Revenue(TTM)16.70K
Net Income(TTM)-11.30M
Analysts82.86
Price Target35.7 (6846.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-211.71%
Min EPS beat(2)-357.52%
Max EPS beat(2)-65.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-98.27%
Min Revenue beat(2)-100%
Max Revenue beat(2)-96.54%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 54.16
P/FCF N/A
P/OCF N/A
P/B 11.14
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.2
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-3.61
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0.01
BVpS0.05
TBVpS-0.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -263.59%
ROE -13916.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.97%
FCFM N/A
ROA(3y)-104.64%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.38
Altman-Z -21.67
F-Score5
WACC7.34%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-96.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.29%
EPS Next Y78.1%
EPS Next 2Y34.54%
EPS Next 3Y23.49%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-66.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y23.21%
EBIT Next 5YN/A
FCF growth 1Y-136.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.44%
OCF growth 3YN/A
OCF growth 5YN/A

LUCY SCIENTIFIC DISCOVERY IN / LSDI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for LUCY SCIENTIFIC DISCOVERY IN?

ChartMill assigns a fundamental rating of 2 / 10 to LSDI.


What is the valuation status for LSDI stock?

ChartMill assigns a valuation rating of 1 / 10 to LUCY SCIENTIFIC DISCOVERY IN (LSDI). This can be considered as Overvalued.


How profitable is LUCY SCIENTIFIC DISCOVERY IN (LSDI) stock?

LUCY SCIENTIFIC DISCOVERY IN (LSDI) has a profitability rating of 0 / 10.


What is the earnings growth outlook for LUCY SCIENTIFIC DISCOVERY IN?

The Earnings per Share (EPS) of LUCY SCIENTIFIC DISCOVERY IN (LSDI) is expected to grow by 78.1% in the next year.